Study guide

23.1 Mood & Psychotic Disorders in Medical Patients

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

23.1 Mood & Psychotic Disorders in Medical Patients

Key Takeaways Explain This Topic AI

SSRIs are the commonest drug cause of hyponatraemia through SIADH, particularly in older patients, and increase upper gastrointestinal bleeding risk with NSAIDs.

Lithium has a narrow therapeutic index of 0.4-1.0 mmol/L; ACE inhibitors, thiazides, NSAIDs and dehydration precipitate toxicity, which causes coarse tremor, ataxia and seizures.

Clozapine is reserved for treatment-resistant schizophrenia and requires mandatory neutrophil monitoring because of agranulocytosis, and it also causes myocarditis and severe constipation.

Last updated: September 2026

Psychiatric morbidity is prevalent among general medical inpatients, frequently complicating medical management, prolonging hospitalisation, and escalating morbidity. For MRCP(UK) Part 1, candidates must master the diagnostic features of mood and psychotic disorders, the pharmacology and adverse effect profiles of psychotropic medications, emergency toxidromes (Serotonin Syndrome vs Neuroleptic Malignant Syndrome), alcohol withdrawal syndromes, and the statutory legal frameworks governing capacity and compulsory treatment in the United Kingdom.

  • 1. Mood & Psychotic Disorders in the Medical Setting
  • Major Depressive Disorder (MDD)

Depression affects up to 20–30% of medical inpatients, particularly those with chronic medical illnesses (e.g. stroke, myocardial infarction, end-stage renal disease, diabetes, and Parkinson's disease).

Diagnostic Criteria (DSM-5 / ICD-11): Diagnosis requires at least 5 of 9 symptoms present nearly every day for at least 2 weeks , representing a change from previous functioning. At least one symptom must be a core symptom :

Persistent low or depressed mood most of the day.

Anhedonia (markedly diminished interest or pleasure in almost all activities).

Significant unintentional weight loss/gain or change in appetite.

Insomnia (particularly early morning wakening) or hypersomnia.

Psychomotor agitation or retardation (observable by others).

Fatigue or loss of energy.

Feelings of worthlessness or excessive, inappropriate guilt.

Diminished ability to think, concentrate, or indecisiveness.

Recurrent thoughts of death, suicidal ideation, or suicide attempts.

Somatic Symptom Confounding in Medical Illness: Fatigue, anorexia, weight loss, and psychomotor slowing can stem directly from underlying physical illness (e.g. malignancy, congestive cardiac failure, hypothyroidism, chronic kidney disease). In medical inpatients, diagnostic emphasis must be placed on cognitive and affective symptoms: pervasive anhedonia, excessive guilt, feelings of hopelessness, worthlessness, and suicidal ideation.

Medical Screening Tools: The Patient Health Questionnaire-9 (PHQ-9) and Hospital Anxiety and Depression Scale (HADS) are validated bedside instruments. HADS specifically omits somatic symptoms to minimize confounding by physical disease.

Bipolar Affective Disorder (BPAD)

Bipolar I Disorder: Characterized by at least one manic episode. Major depressive episodes are common but not strictly required for diagnosis.

Bipolar II Disorder: Characterized by at least one hypomanic episode AND at least one major depressive episode, with no history of full manic episodes .

Mania vs Hypomania:

Mania: Elevated, irritable, or expansive mood with increased energy lasting ≥7 days (or any duration if hospitalisation is required); marked impairment in social or occupational functioning; presence of psychotic features (grandiose delusions, auditory hallucinations).

Hypomania: Elevated or irritable mood lasting ≥4 consecutive days; clearly observable change in functioning, but without significant functional disruption , no hospitalisation required , and no psychotic symptoms .

Lithium Carbonate Therapy:

Gold standard mood stabilizer for prophylaxis of bipolar affective disorder and acute mania; uniquely reduces long-term completed suicide risk.

Narrow Therapeutic Index: Target maintenance serum trough level is 0.6–0.8 mmol/L (0.8–1.0 mmol/L in acute mania). Levels must be drawn exactly 12 hours post-dose .

Adverse Effects: Fine resting tremor, polyuria/polydipsia (nephrogenic diabetes insipidus via uncoupling of aquaporin-2 channels), hypothyroidism, goitre, weight gain, hyperparathyroidism/hypercalcaemia, and chronic tubulointerstitial nephropathy.

Toxicity Precipitants: Dehydration, low-sodium diets, and medications that decrease renal lithium clearance: NSAIDs, Thiazide diuretics (highest risk via compensatory proximal tubular sodium/lithium reabsorption), ACE inhibitors, and ARBs .

Clinical Toxicity: Levels >1.5 mmol/L produce coarse tremor, ataxia, dysarthria, nausea, vomiting, and diarrhoea; levels >2.0 mmol/L trigger hyperreflexia, myoclonus, seizures, stupor, coma, and life-threatening arrhythmias. Management involves aggressive IV 0.9% saline rehydration; haemodialysis is indicated for lithium levels >4.0 mmol/L, or >2.5 mmol/L with severe neurological impairment or renal failure.

Schizophrenia & Psychotic Disorders

Schizophrenia is characterized by positive symptoms (delusions, hallucinations, thought disorganisation), negative symptoms (affective flattening, avolition, alogia, anhedonia, asociality), and cognitive dysfunction.

Kurt Schneider's First-Rank Symptoms (FRS): Classically tested, highly specific clinical features strongly suggestive of schizophrenia in the absence of organic brain disease:

Auditory Hallucinations:

Voices arguing or discussing the patient in the third person.

Voices giving a running commentary on the patient's actions.

Thought echo (gedankenlautwerden): hearing one's thoughts spoken aloud.

Thought Alienation:

Thought insertion: Belief that thoughts are being inserted into one's mind from an external agency.

Thought withdrawal: Belief that thoughts are being actively removed or extracted from one's mind.

Thought broadcasting: Belief that one's private thoughts are passively escaping and accessible to others.

Passivity Phenomena (Delusions of Control): Belief that one's somatic feelings, bodily sensations, volitional acts, or impulses are controlled or manipulated by an external force.

Delusional Perception: A normal, real sensory perception is abruptly interpreted with profound, self-referential, delusional significance (e.g. seeing a red traffic light and instantly 'knowing' one has been ordained by royalty).

  • 2. Psychopharmacology in General Medicine
  • Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs selectively inhibit the presynaptic serotonin transporter (SERT), enhancing central 5-hydroxytryptamine (5-HT) neurotransmission. They are first-line for depression and anxiety disorders.

Sertraline: The drug of choice in patients with ischaemic heart disease and post-myocardial infarction (MI) , supported by the SADHART trial demonstrating cardiovascular safety and minimal arrhythmogenic potential.

Citalopram and Escitalopram: Associated with dose-dependent QTc prolongation and risk of Torsades de Pointes via block of cardiac hERG potassium channels. Maximum daily dose is capped at 20 mg in adults >65 years or with hepatic impairment, and 40 mg in younger adults. Avoid concurrent prescription with other QT-prolonging drugs (e.g. clarithromycin, amiodarone, haloperidol).

Upper Gastrointestinal Bleeding Risk: Platelets lack serotonin synthesis machinery and rely entirely on SERT for uptake from plasma; serotonin is essential for platelet aggregation. SSRIs deplete platelet serotonin, increasing upper GI bleeding risk 2- to 3-fold. When combined with NSAIDs, aspirin, or anticoagulants, bleeding risk multiplies synergistically. NICE guidelines mandate co-prescribing a Proton Pump Inhibitor (PPI, e.g. lansoprazole or omeprazole) when SSRIs are used alongside NSAIDs or antiplatelet therapy.

Hyponatraemia: SSRIs are a leading cause of the Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH), particularly in elderly inpatients on diuretics. Check baseline and routine electrolytes.

SSRI Discontinuation Syndrome: Abrupt cessation or missed doses (especially with short half-life agents like paroxetine or venlafaxine) precipitates symptoms within 24–72 hours: electric shock-like sensations ('brain zaps') , vertigo, dizziness, ataxia, flu-like myalgias, nausea, insomnia, and intense anxiety. Avoided by slow dose tapering over 4 weeks.

Antipsychotics: Typical vs Atypical

Classification Representative Agents Receptor Profile Key Clinical Indications Primary Adverse Effects & Exam Pearls

First-Generation (Typical) Haloperidol, Chlorpromazine, Flupentixol Potent antagonism of striatal and mesolimbic Dopamine D2 receptors Acute behavioural disturbance, severe delirium (non-Parkinsonian), acute psychosis - Extrapyramidal Side Effects (EPSE): High incidence.; - Hyperprolactinaemia (amenorrhoea, galactorrhoea, gynaecomastia).; - QTc prolongation and ventricular dysrhythmias.

Second-Generation (Atypical) Olanzapine, Quetiapine, Risperidone, Aripiprazole 5-HT2A and D2 receptor antagonism (Aripiprazole: partial D2 agonist) Schizophrenia, bipolar mania, treatment-resistant depression - Metabolic Syndrome: Weight gain, dyslipidaemia, impaired fasting glucose/diabetes (highest with olanzapine ).; - Stroke & Mortality in Dementia: 3-fold increased ischaemic stroke risk and increased all-cause mortality in elderly dementia patients (MHRA black-box warning).; - Risperidone has highest EPSE/hyperprolactinaemia among atypicals.

Clozapine (Atypical) Clozapine Weak D2, potent D4, 5-HT2A, α1, M1, H1 antagonism Treatment-resistant schizophrenia (failure of ≥2 antipsychotics, at least one atypical, for ≥6 weeks) - Agranulocytosis & Neutropenia: Mandatory FBC monitoring.; - Myocarditis & Cardiomyopathy .; - Severe Constipation / Intestinal Obstruction .; - Lowers seizure threshold.

Extrapyramidal Side Effects (EPSE) Spectrum

Acute Dystonic Reactions: Rapid onset (hours to days) following initiation or dose escalation; painful involuntary muscle spasms (oculogyric crisis [sustained upward deviation of eyes], torticollis, retrocollis, trismus, laryngeal spasm). Emergency treatment: Intravenous or intramuscular anticholinergic agent (e.g. Procyclidine 5–10 mg) .

Akathisia: Unbearable subjective motor restlessness and compulsion to move (pacing, shifting feet, inability to sit still); frequently mistaken for psychotic agitation, leading to inappropriate antipsychotic dose escalation. Treatment: Dose reduction, switch to atypical agent, or add Propranolol (first-line) or low-dose clonazepam.

Parkinsonism: Onset within weeks; bradykinesia, cogwheel rigidity, masked facies, festinant shuffling gait. Treatment: Reduce antipsychotic dose, or add oral anticholinergic (procyclidine, trihexyphenidyl).

Tardive Dyskinesia: Late onset (months to years); choreoathetoid, stereotypic movements of the tongue, lips, and face (lip smacking, grimacing, tongue protrusion) and choreiform limb/trunk movements. Driven by dopamine D2 receptor upregulation and supersensitivity in the striatum. Often irreversible. Anticholinergic drugs paradoxically worsen tardive dyskinesia! Management: Gradual cessation of culprit typical antipsychotic, switch to clozapine (lowest risk of TD), or VMAT2 inhibitors (valbenazine, deutetrabenazine).

Clozapine: Mandatory Clinical Monitoring & Severe Toxicities

Agranulocytosis / Severe Neutropenia: Occurs in ~1% of patients, peaking in the first 18 weeks. Monitored via centralized registry (CPMS/ZTAS) with absolute neutrophil counts (ANC):

Green: ANC ≥ 2.0 × 10^9/L, WBC ≥ 3.5 × 10^9/L (continue therapy).

Amber: ANC 1.5–2.0 × 10^9/L, WBC 3.0–3.5 × 10^9/L (increase monitoring to twice weekly; continue therapy).

Red: ANC < 1.5 × 10^9/L or WBC < 3.0 × 10^9/L ( IMMEDIATE CESSATION ; never re-challenge with clozapine).

Myocarditis & Cardiomyopathy: Most common within the first 2 months. Baseline and regular troponin, CRP, and echocardiograms are required. Any unexplained tachycardia, chest pain, dyspnoea, or heart failure mandates immediate discontinuation.

Gastrointestinal Hypomotility: Potent anticholinergic and antiserotonergic activity induces severe constipation, paralytic ileus, faecal impaction, and fatal bowel necrosis. Prophylactic stimulant/osmotic laxatives (macrogol, senna) are routinely required.

Hypersalivation (Sialorrhoea): Paradoxical muscarinic M4 agonism and impaired swallowing; treated with sublingual ipratropium spray or hyoscine hydrobromide drops.